NASDAQ
4.05USD
+0.54 (+15.38%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
75.7M
P/E
—
EPS
—
Beta
0.19
52W range
2.14-11.88
Day range
3.46–4.10
Open
3.57
Prev close
3.51
Volume
155.9K
Avg volume
268.8K
Dividend
0.00
IPO
2020-07-30
https://www.globenewswire.com/news-release/2026/08/04/3338001/0/en/KLRS-Abbott-Cooper-PLLC-Announces-Investigation-on-Behalf-of-Kalaris-Therapeutics-Inc-Formerly-Allovir-Inc-Stockholders.html · 8/4/2026-0.60
https://www.newsfilecorp.com/release/275547/Kalaris-to-Present-at-Noble-Capital-Markets-21st-Annual-Emerging-Growth-Equity-Conference · 11/24/2025+0.10
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), as well as for the treatment of other exudative and neovascular retinal diseases.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
